No evidence for amyloid pathology as a key mediator of neurodegeneration post-stroke - a seven-year follow-up study
Open Access
- 8 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Neurology
- Vol. 20 (1), 1-11
- https://doi.org/10.1186/s12883-020-01753-w
Abstract
Cognitive impairment (CI) with mixed vascular and neurodegenerative pathologies after stroke is common. The role of amyloid pathology in post-stroke CI is unclear. We hypothesize that amyloid deposition, measured with Flutemetamol (18F-Flut) positron emission tomography (PET), is common in seven-year stroke survivors diagnosed with CI and, further, that quantitatively assessed 18F-Flut-PET uptake after 7 years correlates with amyloid-β peptide (Aβ42) levels in cerebrospinal fluid (CSF) at 1 year, and with measures of neurodegeneration and cognition at 7 years post-stroke. 208 patients with first-ever stroke or transient Ischemic Attack (TIA) without pre-existing CI were included during 2007 and 2008. At one- and seven-years post-stroke, cognitive status was assessed, and categorized into dementia, mild cognitive impairment or normal. Etiologic sub-classification was based on magnetic resonance imaging (MRI) findings, CSF biomarkers and clinical cognitive profile. At 7 years, patients were offered 18F-Flut-PET, and amyloid-positivity was assessed visually and semi-quantitatively. The associations between 18F-Flut-PET standardized uptake value ratios (SUVr) and measures of neurodegeneration (medial temporal lobe atrophy (MTLA), global cortical atrophy (GCA)) and cognition (Mini-Mental State Exam (MMSE), Trail-making test A (TMT-A)) and CSF Aβ42 levels were assessed using linear regression. In total, 111 patients completed 7-year follow-up, and 26 patients agreed to PET imaging, of whom 13 had CSF biomarkers from 1 year. Thirteen out of 26 patients were diagnosed with CI 7 years post-stroke, but only one had visually assessed amyloid positivity. CSF Aβ42 levels at 1 year, MTA grade, GCA scale, MMSE score or TMT-A at 7 years did not correlate with 18F-Flut-PET SUVr in this cohort. Amyloid binding was not common in 7-year stroke survivors diagnosed with CI. Quantitatively assessed, cortical amyloid deposition did not correlate with other measures related to neurodegeneration or cognition. Therefore, amyloid pathology may not be a key mediator of neurodegeneration 7 years post-stroke. Clinicaltrials.gov (NCT00506818). July 23, 2007. Inclusion from February 2007, randomization and intervention from May 2007 and trial registration in July 2007.Keywords
Other Versions
This publication has 73 references indexed in Scilit:
- Cerebrovascular lesions induce transient -amyloid depositionBrain, 2011
- Vascular Contributions to Cognitive Impairment and DementiaStroke, 2011
- Identification of pure subcortical vascular dementia using 11 C-Pittsburgh compound BNeurology, 2011
- The Role of Apolipoprotein E in Alzheimer's DiseaseNeuron, 2009
- FAS and CFL Forms of Verbal Fluency Differ in Difficulty: A Meta-analytic StudyApplied Neuropsychology, 2008
- Poststroke dementiaThe Lancet Neurology, 2005
- Interaction Between a Rat Model of Cerebral Ischemia and β-Amyloid ToxicityStroke, 2005
- Interaction Between a Rat Model of Cerebral Ischemia and β-Amyloid ToxicityStroke, 2005
- Prospective Follow-Up Study Between 3 and 15 Months After StrokeStroke, 2003
- Neuro-imaging in the diagnosis of Alzheimer's disease I. Computer tomography and magnetic resonance imagingClinical Neurology and Neurosurgery, 1992